Numerous strategies targeting early and late steps of the HIV life cycle have been proposed for gene therapy. However, targeting viral and host determinants of HIV entry is the only strategy that would prevent viral DNAmediated CD4
Introduction

H
uman immunodeficiency virus entry involves sequential binding, first with the CD4 receptor and next with a chemokine coreceptor, CCR5 or CXCR4. A 32-bp deletion in the CCR5 gene (D32) confers resistance to HIV infection in homozygotes (Deng et al., 1996) . A hematopoietic stem cell (HSC) transplant for acute myeloid leukemia (AML) in an HIV-infected patient was performed, using allogeneic cells from a CCR5 D32 donor (Hutter et al., 2009) . This study showed for the first time that a cure for HIV infection was possible and further highlighted the interest of targeting CCR5 through a gene therapy approach (Allers et al., 2011) .
Various strategies have been proposed to disrupt CCR5 expression: one targets directly the CCR5 gene with zinc finger nucleases (ZFNs) and induces stable deletions in the CCR5 gene that prevent expression of the molecule at the cell surface (Perez et al., 2008) . This has been shown to prevent CD4 + T cell depletion, but not viral replication, in humanized mice (Holt et al., 2010) . This strategy is currently being tested in a phase 1 clinical trial using genemodified T cell transfer (Tebas et al., 2014) . Another approach relies on CCR5-specific short hairpin RNA (shRNA) (Qin et al., 2003) . A significant effect on HIV replication of a CCR5-specific shRNA was observed if combined with TRIM5a (tripartite motif-5a) and trans-activation response HUMAN GENE THERAPY METHODS 25:232-240 (August 2014) ª Mary Ann Liebert, Inc. DOI: 10.1089 DOI: 10. /hgtb.2014 (TAR) element decoy genes (Walker et al., 2012) . However, a clinical trial to determine safety, using a similar strategy targeting early and late steps of the viral life cycle, failed to show any improvements in immunological or virological parameters (DiGiusto et al., 2010) . Thus, although effective in vitro, in vivo results, either in animal models or clinical trials, failed to fulfill expectations. Additional HIV gene therapy strategies and tools must therefore be devised and tested.
Apart from genetic knockouts, another possibility to modulate CCR5 at the cell surface is to target the CCR5 protein by intracellular antibody (Swan et al., 2006) or intracellular chemokine (intrakine) gene delivery (Yang et al., 1997) . These strategies reduce CCR5 at the cell surface but do not completely abolish expression. Molecular evolution of CCL5 in vitro led to selection of the P2-CCL5 polypeptide, endowed with higher affinity and selectivity for CCR5 than parental CCL5. The soluble P2-CCL5 compound is a potent inhibitor of HIV entry in vitro (Hartley et al., 2003; Jin et al., 2010) . We engineered a P2-CCL5 intrakine bearing a KDEL sequence that allows its specific compartmentalization into the granular endoplasmic reticulum (GER). Sequestration of the protein into the GER should reduce CCR5 expression from the cell surface and thus directly impact the sensitivity of modified cells to HIV infection.
The C46 peptide is derived from the clinically approved gp41-analog peptide fusion inhibitor T20 (enfuvirtide) (Hildinger et al., 2001) . Primary human CD4 + T cells modified by a self-inactivating lentiviral vector encoding the C46 peptide were protected from HIV infection in vitro (Egelhofer et al., 2004; Perez et al., 2005) . Furthermore, a synergistic effect of T20 and low levels of CCR5 was demonstrated (Heredia et al., 2007) . We thus reasoned that coexpression of the P2-CCL5 intrakine with the C46 entry inhibitor should lead to better protection against HIV infection. In the present study, we developed a lentiviral vector combining the C46 peptide with the P2-CCL5 intrakine to improve antiviral efficacy and reduce the likelihood for escape variants to emerge. Our results show that genetically modified cells were protected from HIV infection and thus were conferred a selective advantage in vitro over nontransduced cells. Our results confirm that targeting viral and host determinants represents a promising strategy for HIV gene therapy.
Materials and Methods
Cell culture
HEK-293T/17 cells (CRL-11268; American Type Culture Collection [ATCC], Manassas, VA) were grown in Dulbecco's modified Eagle's medium (DMEM) supplemented with 2 mM l-glutamine, penicillin (100 U/ml), streptomycin (100 lg/ml) (Life Technologies, Cergy-Pontoise, France), and 10% heat-inactivated fetal calf serum (FCS). CEM.NKR-CCR5 cells (CEMR5, cat. no. 4376; obtained from the AIDS Research Reagent Program, Germantown, MD) were cultured in RPMI 1640 supplemented with 10% FCS and antibiotics. Primary human cells were obtained from leukapheresis samples collected from healthy donors after informed consent had been obtained. Cells were grown at a concentration of 1 · 10 6 cells/ml and activated in RPMI, FCS, antibiotics, interleukin-2 (Proleukin, 60 IU/ml; Novartis, Basel, Switzerland), and CD3/CD28 beads (CTS Dynabeads CD3/CD28; Invitrogen, Carlsbad, CA) at 3 beads per cell. Cells were transduced with the indicated lentiviral vectors 3 days after activation and infected with HIV 3-5 days after transduction.
Lentiviral vector design and production
Second-generation self-inactivating (SIN) lentiviral vectors were used in this study. The cassette encoding the C46 peptide was kindly provided by D. von Laer (Innsbruck University, Innsbruck, Austria) and was cloned into pRRLsin.cPPT.hPGK (kind gift from Dr. L. Naldini, TIGET, San Raffaele Telethon Institute for Gene Therapy, San Raffaele Scientific Institute, Milan, Italy) to generate the Lv93 vector. The P2-CCL5 intrakine was constructed by PCR from the previously described phagemid vector (Hartley et al., 2003) . The P2-CCL5 analog was linked at the N terminus with the CCL5 leader sequence, using an NcoItailed forward primer, and at the C terminus with an HA tag (YPYDVPDYA) and an endoplasmic reticulum (ER) retention signal (KDEL), using an XhoI-tailed reverse primer. The resulting P2-CCL5 intrakine (P2i) was further cloned into the lentiviral vector pRRLsin.PPT.hPGK to generate the Lv114 vector. The C46 coding sequence consists of the T20 sequence fused with the CD34 membrane-spanning domain separated by the human IgG2 hinge (Hildinger et al., 2001) . The C46-2A-P2i bicistronic sequence was synthesized (GenScript, Piscataway, NJ) and inserted into the BamHI/ SalI sites in pRRLsin.PPT.hPGK or into the pRRLsin.PPT. EF1a plasmid (described in Dupuy et al., 2005) to generate the Lv163 and Lv203 vectors, respectively. Details on the cloning procedures are available on request. Lentiviral vectors were produced in HEK-293T cells, as described (Marodon et al., 2003) . Briefly, 23.3 lg of the D8.9 packaging plasmid, 30 lg of the transgene plasmid, and 10 lg of the vesicular stomatitis virus (VSV)-G envelope were transfected into 15 · 10 6 cells in T-175 flasks by calcium phosphate precipitation. Vector supernatants were collected 48 hr posttransfection and concentrated by ultrafiltration (Centricon Plus-70; Millipore, Molsheim, France) at 3500 · g at 4°C. Viral stocks were kept frozen at -80°C. Viral titers were determined on HEK-293T cells with various concentrations of vector supernatants in the presence of Polybrene (8 lg/ml; Sigma-Aldrich, Saint-QuentinFallavier, France). Seventy-two hours after transduction, the percentage of cells expressing the transgenes was determined by flow cytometry and used to calculate a viral titer as the number of infectious particles per milliliter. Transductions of cells were performed with cell numbers and multiplicities of infections (MOIs) as indicated in the figure legends in the presence of Polybrene (8 lg/ml; SigmaAldrich).
HIV strains
HIV-1 molecular clones NL4D8 and Yu2 were obtained through the AIDS Research and Reference Reagent Program (gift from A. Moris, Centre Immunologie et Maladies Infectieuses, Paris, France). HIV stocks were prepared with 30 lgo fH I Vp l a s m i dt r a n s f e c t e di n t o 15 · 10 6 293T cells in T-175 flasks by calcium phosphate precipitation. Supernatants were collected 48 hr posttransfection and frozen at -80°C. Viral titers (ng/ml) were determined by p24 ELISA with standard and unknowns measured in duplicate (Retrotek; ZeptoMetrix, Buffalo, NY).
Flow cytometry and cell sorting
Cells were washed twice in 1· phosphate-buffered saline (PBS) and stained with the cell viability dye eFluor 780 (eBioscience, San Diego, CA). The following monoclonal antibodies were used for cell surface staining: anti-CCR5 conjugated with allophycocyanin (APC) (2D7; BD Biosciences, Pont-de-Claix, France), anti-CD4 conjugated with peridinin chlorophyll protein complex (PerCP) (RPAT-4; BioLegend/Ozyme, Saint-Quentin-en-Yvelines, France), and the human IgG1 2F5 monoclonal antibody (mAb) directed to the EDLKWA gp41 epitope (Polymun, Klosterneuburg, Austria). Cells were washed and stained with a phycoerythrin ( 
DNA extraction and HIV PCR
We used a PureLink genomic DNA mini kit (Invitrogen, Saint Aubin, France) for DNA extraction. To detect HIV in a semiquantitative fashion, the SK38 and SK39 primers were used to detect gag viral DNA, and HLA-DQ-specific DQ28 and DQ29 were used to quantify total cellular DNA in the same tube, as described (Marodon et al., 1999) . PCR conditions were as follows: 1 cycle at 94°C for 3 min; followed by 30 cycles at 94°C for 30 sec, 60°C for 30 sec, and 72°C for 30 sec; with a final extension cycle at 72°C for 10 min. Fractions (15 ll) of each PCR were run on a 4% agarose gel (Invitrogen) and analyzed on Quantum ST4 camera for gel electrophoresis (Vilber Lourmat, Marne-laVallée, France).
Statistical analysis
Two-tailed p values were calculated with Prism version 6.0 software (GraphPad Software, San Diego, CA) for the Mac, using a parametric unpaired t test with a confidence interval of 95%.
Results
Lentiviral vector designed to interfere with both viral and host determinants of HIV entry
A series of mono-and bicistronic second-generation selfinactivated lentiviral vectors was constructed (Fig. 1A) . Notably, we generated the Lv163 bicistronic lentiviral vector coexpressing the C46 peptide and the P2-CCL5 intrakine (P2i) under the control of the phosphoglycerate kinase (PGK) promoter (Fig. 1A) . In our vectors, therapeutic cassette expression can be directly monitored by flow cytometry, using the 2F5 antibody, which binds to the C46 peptide (Hildinger et al., 2001 ). To facilitate the initial studies, we sorted Lv163-transduced CEMR5 cells on the basis of 2F5 staining by fluorescence-activated cell sorting (FACS) to generate CEMR5 cells expressing high and stable levels of C46 (CEMR5-163 cells) (Fig. 1B) . CEMR5-163 cells expressed higher intracellular levels of CCL5 than did parental CEMR5 cells (Fig. 1B) , showing that staining for CCL5 detected P2i as well. A lower level of expression of CCR5 was observed at the cell surface of CEMR5-163 cells compared with parental CEMR5 cells, showing that expression of intracellular P2i correlated with reduced cell surface CCR5 expression (Fig. 1B) .
Bicistronic lentiviral vectors expressing C46 fusion inhibitor and CCL5 intrakine prevent HIV infection
We next determined whether the high-level C46 expression and low-level CCR5 expression that we observed on the CEMR5-163 cell line described previously would have any impact on HIV infection. For this, we challenged CEMR5-163 or control CEMR5 cells with two different strains of HIV (the R5-tropic NL4D8 and Yu2 strains) and monitored HIV infection overtime by p24 ELISA in the supernatant and by HIV gag-specific DNA PCR at the end of the culture (Fig. 2) . Control cells exhibited high levels of p24 (up to 1 · 10 5 pg/ml of supernatant from day 7 to day 11 postinfection) irrespective of the viral strain. Undetectable or low levels of p24 were measured in CEMR5-163 cells infected with NL4D8 virus (50 ng of p24), showing that expression of the transgenes had a protective effect at this dose of p24. This was confirmed by the lack of detectable provirus in challenged cultures (Fig. 2B) , showing that expression of the transgenes provided complete protection. At the same dose, the Yu2 strain was more aggressive because CEMR5 control cells were all dead by day 10 from cytopathic effect (data not shown). Compared with controls, there was some viral replication detected in the culture infected with the Yu2 virus at 50 ng of p24, as evidenced by p24 detection on day 7 and day 11 postinfection (Fig. 2C) . However, CEMR5-163 cells were entirely protected from viral infection if infectious doses of Yu2 were reduced to 0.5 ng of p24, whereas HIV was still detectable and highly pathogenic in control cells at this dose (Fig. 2D) . Low p24 production in transduced cells could be due to increase cell death after HIV challenge. To the contrary, analysis with the viability dye included in our staining showed that the number of live cells dropped only in nontransduced cells, probably owing to HIV-related cell death (data not shown). Altogether, these results demonstrate that the lentiviral vector Lv163 protected genetically modified cells from infection.
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C46 fusion inhibitor and P2-CCL5 intrakine act in synergy to inhibit HIV infection
To document the advantage of coexpressing the P2-CCL5 intrakine and the C46 peptide, we tested the synergy of the transgenes in the inhibition of HIV infection. For this, we sorted CEMR5 cells expressing low levels of CCR5 after transfection with the Lv114 plasmid (CEMR5-114 in Fig. 3A) . Low levels of CCR5 did not confer protection against HIV challenge, as monitored by p24 and gag detection ( (Fig. 3B) . Thus, low CCR5 expression and 50-60% of C46 expression, two conditions in which cells were not protected, conferred protection to HIV infection if combined together.
Selective advantage for CEMR5 cells expressing C46 fusion inhibitor and P2-CCL5 intrakine
Our results so far demonstrate that the combination of two viral entry inhibitors could prevent HIV infection. We next asked whether this protection could prevent HIV-induced cell death and thus lead to better growth compared with nonprotected cells, a process that we referred to as a selective advantage. For that, gene-modified CEMR5 cells were infected or not with the R5-tropic HIV strain NL4D8 or Yu2, and the frequencies of 2F5 + cells and the median of fluorescence intensity (MFI) of CCR5 in 2F5 + cells were determined at the end of culture. A significant increase in the frequencies of 2F5
+ cells was observed when HIV-infected cultures were compared with noninfected ones (Fig. 4A) . Overall, there was a2.1-foldincreaseintheproportionsof2F5 + cells in cultures in the presence of HIV (Fig. 4B) . We assessed whether 2F5 + cells would also be enriched in CCR5 lo cells, as expected from the action of the P2-CCL5 intrakine. Indeed, the MFI of CCR5 was lower on 2F5 + cells in cultures infected with HIV compared with noninfected cultures (Fig. 4C and D) . Altogether, these results demonstrate that 2F5 + CCR5 lo CEMR5 cells were enriched on HIV infection in vitro.T h e s er e s u l t sc o n v e r g et o show that expression of the therapeutic transgenes conferred a selective advantage to gene-modified cells.
Expression of C46 peptide and of P2-CCL5 intrakine efficiently protects primary human CD4 + T cells from infection
To determine whether the therapeutic transgenes would have similar effects on primary human CD4
+ Tc e l l s ,t h en a t u r a l target for HIV, we transduced activated peripheral blood mononuclear cells (PBMCs) with a new lentiviral vector in which the elongation factor-1a (EF1a) promoter replaces the PGK promoter (Fig. 5A ). Cultures were then challenged with two different HIV strains at two different doses. Transduction of PBMCs at an MOI of 40 led to reproducible expression of the C46 peptide in 60-80% of the cells (Fig. 5B) . Expression of P2-CCL5 was not monitored because activated human CD4 + T cells express high levels of CCL5, rendering difficult the detection of the vectorencoded CCL5 by flow cytometry (data not shown). However, prevention of CCR5 expression at the surface of 2F5 + cells was readily observed, indirectly showing that the P2-CCL5 intrakine affected CCR5 expression in primary T cells (Fig. 5C) . A marked difference in p24 was observed when protected cultures were compared with mock-transduced cells, showing that expression of the transgenes affected viral replication (Fig. 5D) . Furthermore, under conditions in which the number of 2F5 + cells was set to lower frequencies by diluting transduced into nontransduced cells, a progressive increase in 2F5 + cells was observed in HIV-infected relative to noninfected cultures, showing that transduced cells possessed a selective advantage over nonprotected cells (Fig. 5E ).
Discussion
We devised a lentiviral vector expressing a combination of two HIV entry inhibitors to reduce the risks of viral escape and improve the likelihood for selective advantage. The combination of two entry inhibitors might be particularly interesting in view of data showing that the mere presence of viral DNA before integration might be the initiator of CD4 + T cell death, the initial event in the development of AIDS (Doitsh et al., 2014) . Thus, we believe that gene therapy and vaccines should aim toward the same goal, that is, preventing the virus from getting into the CD4 + T cell. HIV gene therapy has moved from single agents to combinatorial approaches targeting various steps of the viral cycle (Peterson et al., 2013) . For instance, a lentiviral vector including a CCR5 shRNA, a chimeric TRIM5a molecule, and a TAR decoy has been developed (Anderson et al., 2007) and promising results were published in humanized mice although the strategy failed to impact viral loads (Walker et al., 2012) . However, the functional impact of overexpressing TRIM5a, APOBEC (apolipoprotein B mRNA-editing enzyme, catalytic polypeptide-like), or other mRNA-editing molecules has not been tested. In the vector described here, we took care not to incorporate mRNAediting molecules, or potential immunogens or proinflammatory molecules, that might prevent gene transfer efficacy or lead to unforeseeable side effects. Indeed, several reports attest that small interfering RNAs (siRNAs) might initiate a proinflammatory response in vivo ( Judge et al., 2005; Robbins et al., 2008) . Zinc finger nucleases might induce a complete loss of CCR5 and/or CXCR4 expression in targeted cells (Holt et al., 2010; Didigu et al., 2014) but the side effects of that protocol, such as off-target cleavage (Pattanayak et al., 2011) , alteration of hematopoiesis, or homing properties for modified cells, still need to be fully evaluated. We chose a less aggressive strategy allowing residual expression of CCR5 on the cell surface. A partial downregulation of CCR5 expression alone might not be enough to completely protect CD4 + T cells from infection but we show that it significantly increased the potency of the C46 peptide fusion inhibitor. This observation suggests that complete knockout of CCR5 might not be needed if modulation of CCR5 is combined with other therapeutic transgenes. Furthermore, the P2-CCL5 intrakine remains closely related to the self-derived CCL5, and is therefore unlikely to elicit a strong immune response. The C46 peptide is also a good candidate for gene therapy because it is derived from an already approved medication. Despite the synergy between these two HIV inhibitors, we observed that gene-modified cells were not protected after challenge with high doses of the patient-derived HIV Yu2, in contrast to the molecular HIV construction NL4D8. The viral dose that a CD4 + T cell might encounter in vivo is likely to be lower than the dose used in vitro, in our challenge experiments. Nevertheless, one might think of adding another therapeutic transgene to the vector to improve efficacy. The HIV-inhibiting integrase-binding domain (IBD) of lens epithelium-derived growth factor/p75 might represent a useful adjunct in our vector (De Rijck et al., 2006) .
A major concern for antifusion therapeutic strategies is the rapid emergence of enfuvirtide-resistant variants (Greenberg and Cammack, 2004 ). However, it should be stressed that enfuvirtide-resistant HIV strains are still susceptible to membrane-bound C46 peptide (Egelhofer et al., 2004) , showing that the resistance to C46 is not equivalent to that toward T20. Increasing local concentrations of T20 at the viral-cellular interface during fusion might be the cause of this improved efficacy. Of note is the fact that the C46 peptide is 10 amino acids longer than T20; that may also impact on the wider effect of C46 on T20-resistant HIV strains (Lohrengel et al., 2005) . In any case, our strategy targeting essential steps of viral infection (fusion and attachment to CCR5) is likely to reduce the possible emergence of doubly-resistant escape variants that are generated during retrotranscription.
Another important feature needed for successful HIV gene therapy will be the selective advantage conferred to modified lymphocytes. We observed a selective advantage in vitro with a 2.1-fold enrichment in 2F5 + CCR5 lo cells in HIV-challenged compared with noninfected cultures. Although this may appear modest, the selective advantage observed in vitro might be severely limited by indirect toxic
FIG. 5. Expression of C46 peptide and of P2-CCL5 intrakine efficiently protects primary human CD4
+ Tc e l l sf r o m infection. (A) Al e n t i v i r a lv e c t o rc o e x p r e s s i n gC 4 6p e p t i d ea n dP 2 -C C L 5i n t r a k i n ew a sd e r i v e df r o mt h eL v E F 1 a-GFP vector and is referred to as Lv203. (B) Expression levels of C46 peptide on anti-CD3/CD28-activated human peripheral blood mononuclear cells (PBMCs) 3 days after transduction with the Lv203 vector at an MOI of 40. Cells were stained for C46 expression with the 2F5 monoclonal antibody (mAb) and revealed with a secondary anti-human mAb labeled with phycoerythrin. NT, nontransduced. (C) Frequencies of CCR5 + cells gated in CD4 + 2F5 + cells, as defined in (B), were determined by flow cytometry 22-23 days after transduction on CD3/CD28-activated PBMC cultures from three different donors in two independent experiments (**p < 0.05). (D) HIV replication was monitored by p24 ELISA from the supernatant of CD4 + Tcel lsH IV -in fe ct edcu ltu re s,ei th erm oc kt ra nsduced (NT, nontransduced) or transduced with the Lv203 vector after infection with either 0.5 or 25 ng of p24 (NL4D8 R5-tropic virus) on 5 · 10 5 or 1 · 10 6 cells, respectively. Results shown are cumulative of two independent experiments with four unrelated healthy donors. (E) Selective advantage of transduced CD4 + TcellsatanMOIof20oninfectionwithYu2orNL4D8virus(25ngofp24),as indicated. Transduced cells were diluted with mock-transduced cells from the same donor to fix the frequencies of transduced cells at 20% before infection. The fold change represents the ratio of 2F5 + cells determined by flow cytometry in HIV-infected versus noninfected cultures in one experiment with two healthy donors. Color images available online at www.liebertpub.com/hgtb effects linked to massive cell death in culture. A 2.2-fold in vivo selective advantage was reported for CCR5 and CXCR4 double-knockout cells (Didigu et al., 2014) . A selective advantage has also been shown in humanized mice reconstituted with zinc finger-modified CD34 + progenitors (Holt et al., 2010) or with CD4 + T cells modified to express the C46 peptide (Kimpel et al., 2010) . We are currently determining the selective advantage conferred by our vector to primary human T cells in vivo in advanced models of humanized mice. It will also be important to determine whether our protocol is able to significantly impact viral loads and CD4 + T cell deletion. In summary, our results functionally validate a new gene transfer vector combining two HIV entry inhibitors. Further work is needed to appreciate the impact of this approach in preclinical models of HIV gene therapy.
